Industry News

Cerus Corporation announced today that Kevin Green, Cerus' vice president, finance and chief financial officer, is scheduled to present a corporate update at the Cantor Fitzgerald Healthcare Conference at 1:30 PM ET on Wednesday, July 13, 2016.. A live webcast of the presentation will be available from the Investor Relations page of the Cerus web site at http://www.cerus.com/ir. A replay will be available for approximately two weeks following the..."/>
Cerus to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference on July 13, 2016
Viveve Medical, Inc., a medical technology company focused on women's health, today announced six new distribution partnerships that expand commercial availability of the Viveve System to fourteen additional countries in Latin America. The new relationships provide for distribution of the Viveve System in: Argentina, Peru, Paraguay and Chile, Columbia and Ecuador, Mexico, Panama, Costa Rica, Guatemala and Dominican Republic, Uruguay, and Venezuela and..."/>
Viveve(R) Expands in Latin America With Six New Distribution Partnerships
Amedica Corporation, a company that develops and commercializes silicon nitride ceramics, today announced the pricing of an underwritten public offering of units for gross proceeds of $11 million, prior to deducting underwriting discounts and commissions and offering expenses payable by Amedica. The offering is comprised of Class A Units, priced at a public offering price of $1.00 per unit, with each unit consisting of one share of common stock and..."/>
Amedica Announces Pricing of $11 Million Public Offering
HealthSouth Corporation and BJC HealthCare today announced they have filed a certificate of need with the State of Missouri to build a 35- bed inpatient rehabilitation hospital on the third floor of BJC's Barnes-Jewish St. Peters Hospital located in St. Pending approval, the hospital will serve as a satellite location of The Rehabilitation Institute of St."/>
HealthSouth and BJC HealthCare Announce Intent To Construct 35-Bed Rehabilitation Hospital at Barnes-Jewish St. Peters Hospital
Verastem, Inc., focused on discovering and developing drugs to treat cancer, today announced the publication of preclinical research in the journal Nature Medicine by the Company’ s researchers and scientific collaborators."/>
Study Published in Nature Medicine Highlights Potential Role of FAK Inhibition in Pancreatic Cancer
Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Joseph "Jay" Hagan, Chief Operating Officer of Regulus, will present a company overview at Cantor Fitzgerald's 2 nd Annual Healthcare Conference on Wednesday, July 13, 2016 at 2:00 p.m. ET. Regulus Therapeutics Inc. is a biopharmaceutical company leading the discovery and..."/>
Regulus to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference
K2M Group Holdings, Inc., a global medical device company focused on designing, developing and commercializing innovative and proprietary complex spine and minimally invasive spine technologies and techniques, today announced second quarter 2016 financial results will be released after the market close on August 3rd.. Management will host a conference call at 5:00 p.m. Eastern Time on August 3rd to discuss the results of the quarter, and to host a..."/>
K2M Group Holdings, Inc. to Release Second Quarter 2016 Financial Results on August 3rd
Brookdale Senior Living associate who has experienced firsthand dementia's impact on her family has been named the 2016 Walk to End Alzheimer's ® Event Chair in Nashville. The Alzheimer's Association has appointed Brookdale director of communications Sandy LaFave to the post. Walk to End Alzheimer's is the world's largest event to generate awareness and funds for Alzheimer's care, support and research."/>
2016 Nashville Walk to End Alzheimer's® Chair Has Felt Dementia's Impact
Aimmune Therapeutics, Inc., a biopharmaceutical company developing CODIT™ treatments for life-threatening food allergies, today announced that Mary Rozenman, Ph.D., Senior Vice President of Corporate Development and Strategy at Aimmune, will present a company overview at Cantor Fitzgerald’ s 2 nd Annual Healthcare Conference in New York City, on Tuesday, July 12, 2016, at 3:30 p.m. Eastern Time. The live webcast of the presentation will be accessible on the..."/>
Aimmune Therapeutics to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference
Hologic, Inc. announced today that it has notified holders of the 2.00% Convertible Exchange Senior Notes due 2037 issued November 23, 2010, and Wilmington Trust Company, the trustee, paying agent and conversion agent for the notes, that holders are eligible to convert the notes. This conversion right is subject to the terms of the base indenture governing the notes dated as of December 10, 2007, as supplemented by the second..."/>
Hologic Delivers Notice that Holders of 2.00% Convertible Exchange Senior Notes Due 2037 are Eligible to Convert
Alcobra Ltd., an emerging pharmaceutical company focused on the development of new medications to treat patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder and Fragile X Syndrome, today announced that it will be presenting at the upcoming Cantor Fitzgerald 2 nd Annual Healthcare Conference. About Alcobra Ltd. Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and..."/>
Alcobra Ltd. to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference
Cara Therapeutics, Inc., a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will present a company overview at Cantor Fitzgerald’ s 2 nd Annual Healthcare Conference on Tuesday, July 12, 2016, at 1:00 p.m. ET in New York City.. A live webcast of the..."/>
Cara Therapeutics to Webcast Presentation at Cantor Fitzgerald’s 2nd Annual Healthcare Conference
PositiveID Corporation, a life sciences company focused on detection and diagnostics, announced today the Company will effect a reverse split of its common stock at a ratio of 1:50, commencing at the open of trading today, July 5, 2016.. The Company’ s ticker symbol will be PSIDD for 20 trading days to designate that it is trading on a post-reverse split basis. PositiveID’ s post-split common stock will trade under the new CUSIP Number 73740 J407."/>
PositiveID Announces Reverse Stock Split
pSivida Corp., a leader in the development of sustained release drug delivery products primarily for eye diseases, announced the completion of two animal studies of an injectable, sustained-release insert utilizing pSivida’ s proven Durasert™ technology to deliver a tyrosine kinase inhibitor for treatment of wet age-related macular degeneration. The preclinical study data demonstrated that at the completion of the studies in..."/>
PSivida Announces Successful Completion of Two Preclinical Studies of Durasert™ Sustained-Release Insert Delivering Repurposed Cancer Drug to Treat Wet AMD
Premier Inc., a leading health care improvement company, which unites an alliance of 3,600 hospitals and 120,000 other providers, today announced a three-year contract that will make OBP's portfolio of disposable vaginal specula with built-in LED light source, including the OfficeSPEC and ER-SPEC brands, available at specially..."/>
OBP Medical's ER-SPEC and OfficeSPEC Awarded New Group Purchasing Contract with Premier
Revance Therapeutics, Inc., a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced that Julian S. Gangolli, President, North America, of GW Pharmaceuticals plc, has been elected to Revance’ s Board of Directors and will serve as a member of the Audit Committee, effective July 1, 2016.. Gangolli brings over two decades of senior management experience building and running operations and..."/>
Revance Appoints Industry Leader Julian S. Gangolli to its Board of Directors
Therapix Biosciences,, a pharma company specializing in the development and commercialization of cannabinoid-based drugs, announced today that it entered into a binding memorandum of understandings with Yissum, the technology transfer company of the Hebrew University of Jerusalem, to receive an exclusive, worldwide license to use a patent-protected formulation for nasal administration of cannabinoid substances."/>
Therapix Biosciences Signed a Binding MOU with Yissum, the Technology Transfer Company of the Hebrew University of Jerusalem, to Receive a License to Use a Formulation for Nasal Administration of Cannabinoid Substances
CytoSorbents Corporation has closed upon a USD10 million senior debt facility with the Life Sciences Group of Bridge Bank, a division of Western Alliance Bank, the company said. CytoSorbents Corporation and its US operating subsidiary, CytoSorbents Medical, Inc. entered into a loan and security agreement with Bridge Bank, securing an initial USD5.0 million four-year term loan. Interest-only monthly payments are due for the first year and then monthly principal and interest..."/>
CytoSorbents closes USD10m debt financing with Bridge Bank
XOMA Corp., Navidea Biopharmaceuticals Inc., Radius Health Inc., and Cara Therapeutics Inc.."/>
Why Investors Love These Biotech's Stocks? - XOMA Corp., Navidea Biopharma, Radius Health, and Cara Therapeutics
ARIAD Pharmaceuticals, Inc. today announced that it will report its second quarter 2016 financial results on Thursday, July 28, 2016, before the market opens. Following the announcement, at 8:30 a.m. Eastern Time, company management will host a conference call and webcast discussion of the results and provide a general corporate update. The live webcast can be accessed by visiting the investor relations section of the Company’ s website at..."/>
ARIAD to Webcast Conference Call on Second Quarter 2016 Financial Results
BioCryst Pharmaceuticals, Inc. today announced that the National Institute of Allergy and Infectious Diseases has provided additional funding for efficacy studies of BCX4430 in non-human primates to further assess effective dose regimens.. The funding represents an additional $5.5 million to BioCryst for the development of BCX4430 as a treatment for hemorrhagic fever viruses. The new total NIAID contract amount to advance the..."/>
BioCryst Receives Additional NIAID Funding to Advance Development of BCX4430 to Treat Hemorrhagic Fever Virus Diseases
Intellipharmaceutics International Inc., a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today provided an update on its Rexista TM XR new drug application candidate.. In February 2016, Intellipharmaceutics requested a waiver of the application user fee under the small business waiver provision, section 736 of the Federal..."/>
Intellipharmaceutics Reports Update on Rexista™ XR: FDA Grants Waiver of NDA Filing Fee, and Topline Pharmacokinetics Results Indicate No Food Effect

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Financials947 Articles
Information Technology902 Articles
Consumer Discretionary759 Articles
Industrials600 Articles
Health Care594 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.